Cochlear Ltd.
http://www.cochlear.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cochlear Ltd.
Soterios Topical Could Take On JAK Class In Alopecia Areata
The UK biotech unveils Phase II data showing an ability to reduce severity of mild-to-moderate AA, with full hair restoration in some patients. If approved, STS-01 will compete with Olumiant and Litfulo.
Senate Work On Biosecurity Issues Continues Even As House Is Current Focus Of Legislative Activity
US FDA Principal Deputy Commissioner Namandjé Bumpus recently attended a biotech-themed roundtable with the Senate Select Committee on Intelligence and national security officials as Congress’ pulls the FDA into its worries about Chinese influence of the pharma industry.
Syngene Chief: Large Cap Biopharma Taking China 'Rotation' More Seriously
A material shift in China derisking discussions by big biopharma against the backdrop of the proposed US BIOSECURE Bill is seen presenting opportunities for Syngene, though the tight US biotech funding environment dampened demand for the Indian CRDMO’s R&D services in Q4.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
Company Information
- Industry
-
Medical Devices
- Biomaterials
- Implantable Devices
- Other Names / Subsidiaries
-
- Cochlear Americas
- Entifie Medical Systems Inc.
- Nobel Biocare USA
- Cochlear Bone Anchored Solutions, Sycle, LLC
- Cochlear Malaysia Sdn. Bhd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice